Sanofi-aventis and Oxford BioMedica Enter Global Licensing Agreement to Develop and Commercialise TroVax® For Cancer
Sanofi-aventis and Oxford BioMedicaEnter Global Licensing Agreementto Develop and Commercialise TroVax® For CancerParis, France - March 28, 2007 - Sanofi-aventis (EURONEXT: SAN; NYSE: SNY) and Oxford BioMedica (LSE: OXB) announced today that they have entered into an exclusive global license agreement to develop and commercialise TroVax® for the treatment and prevention of cancers.TroVax® is Oxford BioMedica’s lead cancer immunotherapy. This therapeutic vaccine has been evaluated in clinical trials involving more than 180 patients with various forms of cancer. A Phase III trial -